BCRX · Biocryst Pharmaceuticals Inc

$9.74 -0.07 (-0.71%) At close · Aug 14

Market Cap

$2.49B

255.54M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	Former President and Chief Executive Officer	$728,466	—	—	$11,132,458	$1,052,633	$37,525	$12,951,082
Charles Gayer	President and Chief Executive Officer; Former Chief Commercial Officer	$609,397	—	$3,358,230	$4,893,653	$749,088	$17,500	$9,627,868
Babar Ghias	Chief Financial Officer	$271,515	$160,000	$2,124,571	$3,675,166	$506,400	$10,500	$6,748,152
Alane P. Barnes	Chief Legal Officer and Corporate Secretary	$542,519	—	$867,721	$3,634,923	$553,369	$17,500	$5,616,032
Helen Thackray	Former Chief R&D Officer	$425,999	—	$1,168,791	$1,255,458	$756,112	$733,264	$4,339,624
Anthony Doyle	Former Chief Financial Officer and Treasurer	$151,925	—	$708,694	$1,165,816	—	$114,700	$2,141,135

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	President, Chief Executive Officer, Interim Chief Financial Officer, and Director	$705,536	—	$2,675,919	$4,002,134	$899,558	$34,139	$8,317,286
Helen Thackray	Chief R&D Officer	$599,423	—	$930,771	$1,392,012	$629,394	$17,250	$3,568,850
Charles Gayer	Chief Commercial Officer	$544,830	—	$930,771	$1,392,012	$490,347	$17,250	$3,375,210
Anthony Doyle	Former Chief Financial Officer and Treasurer	$549,429	—	$891,973	$1,334,133	$494,486	$17,250	$3,287,271
Alane P. Barnes	Chief Legal Officer and Corporate Secretary	$525,442	—	$891,973	$1,334,133	$472,898	$17,250	$3,241,696

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	President, Chief Executive Officer, Interim Chief Financial Officer, and Director	$665,600	—	$819,825	$2,724,624	$537,472	$30,257	$4,777,778
Helen Thackray	Chief R&D Officer	$576,368	—	$327,930	$1,089,850	$383,285	$16,500	$2,393,933
Alane P. Barnes	Chief Legal Officer and Corporate Secretary	$495,700	—	$411,520	$725,803	$282,549	$16,500	$1,932,072
Anthony Doyle	Former Chief Financial Officer and Treasurer	$528,297	—	$218,620	$725,803	$301,129	$16,500	$1,790,349
Charles Gayer	Chief Commercial Officer	$495,300	—	$218,620	$725,803	$282,321	$16,500	$1,738,544

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	President, Chief Executive Officer, Interim Chief Financial Officer, and Director	$640,000	—	$1,355,325	$4,482,254	$480,000	$25,415	$6,982,994
Helen Thackray	Chief R&D Officer	$554,200	—	$861,030	$1,792,902	$277,100	$12,700	$3,497,932
William Sheridan	MBBS Chief Development Officer	$549,171	—	$680,320	$1,194,012	$219,668	$15,250	$2,658,421
Yarlagadda S. Babu	Chief Discovery Officer	$483,000	—	$680,320	$1,194,012	$193,200	$15,250	$2,565,782
Anthony Doyle	Former Chief Financial Officer and Treasurer	$507,978	—	$361,420	$1,194,012	$203,191	$15,250	$2,281,851
Alane P. Barnes	Chief Legal Officer and Corporate Secretary	$457,200	—	$361,420	$1,194,012	$182,880	$15,250	$2,210,762
Charles Gayer	Chief Commercial Officer	$448,700	—	$361,420	$1,194,012	$179,480	$15,250	$2,198,862

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Megan Sniecinski	Former Chief Business Officer	$286,192	—	—	$6,952,056	—	$690,876	$7,929,124
Jon P. Stonehouse	President, Chief Executive Officer and Director	$583,495	$43,762	$1,405,890	$4,511,089	$492,324	$24,665	$7,061,225
Helen Thackray	Chief R&D Officer	$425,125	$236,500	$1,519,920	$4,395,101	$298,125	$6,625	$6,881,396
Anthony Doyle	Chief Financial Officer and Treasurer	$490,800	$19,632	$857,250	$1,287,761	$220,860	$14,500	$2,890,803
William Sheridan	MBBS Chief Development Officer	$530,600	$21,224	$400,050	$1,287,761	$238,770	$52,826	$2,531,231
Yarlagadda S. Babu	Chief Discovery Officer	$458,945	$18,358	$400,050	$1,287,761	$206,525	$14,500	$2,386,139

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	President, Chief Executive Officer and Director	$566,500	—	—	$4,916,022	$531,094	$21,325	$6,034,941
Anthony Doyle	Chief Financial Officer and Treasurer	$345,455	$50,000	—	$3,468,225	$240,000	$14,250	$4,117,930
William Sheridan	MBBS Chief Development Officer	$515,146	—	—	$1,892,951	$257,573	$14,250	$2,679,920
Yarlagadda S. Babu	Chief Discovery Officer	$445,578	—	—	$1,582,168	$222,789	$14,250	$2,264,785
Megan Sniecinski	Former Chief Business Officer	$456,750	—	—	$1,271,385	$228,375	$55,825	$2,012,335
Thomas R. Staab II	Former Senior Vice President and Chief Financial Officer	$77,113	—	—	—	—	$615,677	$692,790

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	President, Chief Executive Officer and Director	$550,000	—	—	$1,368,767	$350,625	$14,905	$2,284,297
Megan Sniecinski	Former Chief Business Officer	$225,000	—	—	$1,773,364	$153,000	$25,590	$2,176,954
Yarlagadda S. Babu	Chief Discovery Officer	$432,600	—	—	$489,623	$147,084	$14,000	$1,083,307
William Sheridan	MBBS Chief Medical Officer	$500,142	—	—	$382,994	$170,048	$14,000	$1,067,183
Thomas R. Staab II	Former Senior Vice President and Chief Financial Officer	$462,679	—	—	$276,365	$157,311	$14,000	$910,354

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	President, Chief Executive Officer and Director	$550,000	—	—	$3,277,800	$325,188	$14,655	$4,167,643
William Sheridan	MBBS Chief Medical Officer	$485,574	—	—	$1,626,760	$208,797	$28,088	$2,349,219
Thomas R. Staab II	Former Senior Vice President and Chief Financial Officer	$449,203	—	—	$1,141,160	$193,157	$13,750	$1,797,270
Yarlagadda S. Babu	Chief Discovery Officer	$420,000	—	—	$1,141,160	$180,600	$13,750	$1,755,510

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jon P. Stonehouse	President, Chief Executive Officer and Director	$532,823	$243,019	—	$2,910,080	$220,862	$14,405	$3,921,189
William Sheridan	Senior Vice President and Chief Medical Officer	$469,143	$155,618	—	$1,001,288	$141,429	$41,072	$1,808,550
Thomas R. Staab II	Senior Vice President and Chief Financial Officer	$434,002	$143,962	—	$1,001,288	$130,836	$13,500	$1,723,588
Drug Discovery	—	$382,480	$126,872	—	$1,001,288	$115,304	$13,500	$1,639,444

Executive changes

Person	Role	Change	Effective	Filed
Jon P. Stonehouse	director	Appointed	2026-06-11	2026-06-12
Amy E. McKee, M.D.	director	Appointed	2026-06-11	2026-06-12
Theresa M. Heggie	director	Appointed	2026-06-11	2026-06-12
Dr. Helen Thackray	Chief Research and Development Officer	Resigned	2025-09-01	2025-08-11
Charlie Gayer	Chief Executive Officer	Appointed	2026-01-01	2025-07-31
Charlie Gayer	director	Appointed	2026-01-01	2025-07-31
Charlie Gayer	President	Appointed	2025-08-01	2025-07-31
Jon Stonehouse	President and Chief Executive Officer	Retired	2025-12-31	2025-07-31
Babar Ghias	Head of Corporate Development	Appointed	2025-07-07	2025-07-07
Babar Ghias	Principal Accounting Officer	Appointed	2025-07-07	2025-07-07
Babar Ghias	Chief Financial Officer	Appointed	2025-07-07	2025-07-07
Steven Frank	Director	Appointed	2025-05-02	2025-05-01
Jon P. Stonehouse	Interim Chief Financial Officer	Appointed	2025-04-09	2025-04-10
Jon P. Stonehouse	Interim Principal Accounting Officer	Appointed	2025-04-09	2025-04-10
Anthony Doyle	Interim Principal Accounting Officer	Resigned	2025-04-09	2025-04-10
Anthony Doyle	Chief Financial Officer and Interim Principal Accounting Officer	Resigned	2025-04-09	2025-04-10
Anthony Doyle	Chief Financial Officer	Resigned	2025-04-09	2025-03-04
A. Machelle Sanders	director	Appointed	2024-06-12	2024-06-13
Vincent J. Milano	director	Appointed	2024-06-12	2024-06-13
Nancy J. Hutson	director	Appointed	2024-06-12	2024-06-13
Kenneth B. Lee, Jr.	Board of Directors	Retired	2023-12-31	2023-12-01
Anthony Doyle	interim Principal Accounting Officer	Appointed	2023-07-10	2023-07-11
Michael L. Jones	Executive Director, Finance and Principal Accounting Officer	Resigned	—	2023-07-11
Amy E. McKee, M.D.	director	Appointed	2023-06-13	2023-06-14
Jon P. Stonehouse	director	Appointed	2023-06-13	2023-06-14

Key facts CIK 882796 CUSIP 09058V103 13F (30d) 309 filings 302 filers Visit website Investor relations